Menu Search
Equities

Transmedics Group Inc

8T8:DUS

Transmedics Group Inc

Actions
  • Price (EUR)79.76
  • Today's Change1.60 / 2.05%
  • Shares traded55.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Transmedics Group Inc grew revenues 158.53% from 93.46m to 241.62m while net income improved from a loss of 36.23m to a smaller loss of 25.03m.
Gross margin59.34%
Net profit margin8.14%
Operating margin7.84%
Return on assets4.43%
Return on equity19.41%
Return on investment4.78%
More ▼

Cash flow in USDView more

In 2023, Transmedics Group Inc increased its cash reserves by 96.01%, or 193.63m. Cash Flow from Financing totalled 400.42m or 165.72% of revenues. In addition the company used 13.03m for operations while cash used for investing totalled 193.95m.
Cash flow per share1.46
Price/Cash flow per share57.21
Book value per share6.25
Tangible book value per share5.85
More ▼

Balance sheet in USDView more

Transmedics Group Inc has a Debt to Total Capital ratio of 70.78%, a lower figure than the previous year's 399.68%.
Current ratio8.20
Quick ratio7.33
Total debt/total equity2.42
Total debt/total capital0.7078
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.